These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1349727)

  • 1. Optimal drug and behavior therapy for treatment-refractory institutionalized schizophrenics.
    Kuehnel TG; Liberman RP; Marshall BD; Bowen L
    New Dir Ment Health Serv; 1992; (53):67-78. PubMed ID: 1349727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal drug and behavior therapy for treatment-refractory schizophrenic patients.
    Liberman RP; Van Putten T; Marshall BD; Mintz J; Bowen L; Kuehnel TG; Aravagiri M; Marder SR
    Am J Psychiatry; 1994 May; 151(5):756-9. PubMed ID: 8166320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neuroleptic modification of basic schizophrenic disorders].
    Heim M; Morgner J
    Psychiatr Neurol Med Psychol (Leipz); 1987 May; 39(5):274-80. PubMed ID: 2888144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of risperidone on polydipsia in chronic schizophrenia patients.
    Kern RS; Marshall BD; Kuehnel TG; Mintz J; Hayden JL; Robertson MJ; Green MF
    J Clin Psychopharmacol; 1997 Oct; 17(5):432-5. PubMed ID: 9316001
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of higher-dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients].
    Schmidt LG; Schüssler G; Kappes CV; Müller-Oerlinghausen B
    Nervenarzt; 1982 Sep; 53(9):530-6. PubMed ID: 6127637
    [No Abstract]   [Full Text] [Related]  

  • 7. Haloperidol does not affect the level of serum-soluble interleukin-2 receptor in drug-free male schizophrenics.
    Kim CE; Kang DY; Ha KS; Jeong SH; Kim YS
    Biol Psychiatry; 1995 Dec; 38(12):843-5. PubMed ID: 8750045
    [No Abstract]   [Full Text] [Related]  

  • 8. ERPs in schizophrenia: effects of antipsychotic medication.
    Ford JM; White PM; Csernansky JG; Faustman WO; Roth WT; Pfefferbaum A
    Biol Psychiatry; 1994 Aug; 36(3):153-70. PubMed ID: 7948453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
    Levinson I; Levine S
    Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667
    [No Abstract]   [Full Text] [Related]  

  • 10. Strategies for enhancing drug therapy of schizophrenia.
    Schooler NR; Levine J
    Am J Psychother; 1983 Oct; 37(4):521-32. PubMed ID: 6140869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-term therapy of chronic schizophrenic patients with haloperidol decanoate].
    Roncoroni D
    Psychiatr Prax; 1984 Mar; 11(2):56-8. PubMed ID: 6144121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aripiprazole and haloperidol: beneficial combination antipsychotic therapy for a schizophrenic patient.
    Kuo J; Hwu HG
    Clin Neuropharmacol; 2008; 31(3):173-5. PubMed ID: 18520984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.
    Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M
    Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison.
    Kane JM; Marder SR; Schooler NR; Wirshing WC; Umbricht D; Baker RW; Wirshing DA; Safferman A; Ganguli R; McMeniman M; Borenstein M
    Arch Gen Psychiatry; 2001 Oct; 58(10):965-72. PubMed ID: 11576036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of haloperidol dose on iodine-123-IBZM brain SPECT imaging in schizophrenic patients.
    Vallabhajosula S; Hirschowitz J; Machac J
    J Nucl Med; 1997 Feb; 38(2):203-7. PubMed ID: 9025736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes.
    Marder SR; Glynn SM; Wirshing WC; Wirshing DA; Ross D; Widmark C; Mintz J; Liberman RP; Blair KE
    Am J Psychiatry; 2003 Aug; 160(8):1405-12. PubMed ID: 12900301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neuroleptic large dose therapy of schizophrenias].
    Ungvári G; Pethö B
    Psychiatr Neurol Med Psychol (Leipz); 1981 Apr; 33(4):230-6. PubMed ID: 6114506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of treatment refractory schizophrenia.
    Morrison DP
    Br J Psychiatry Suppl; 1996 Dec; (31):15-20. PubMed ID: 8968651
    [No Abstract]   [Full Text] [Related]  

  • 20. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.